After completing the 12-month PGY-2 Pharmacy Residency in Oncology at Mayo Clinic Hospital — Rochester, you will be a proficient independent practitioner capable of providing advanced pharmaceutical care to oncology patients.

The purpose of the PGY-2 Pharmacy Residency in Oncology at Mayo Clinic Hospital — Rochester is to build on Doctor of Pharmacy (PharmD) education and PGY-1 pharmacy residency programs to contribute to the development of clinical pharmacists in specialized areas of practice. PGY-2 residencies provide you with opportunities to function independently as a practitioner by conceptualizing and integrating accumulated experience and knowledge and incorporating both into the provision of patient care or other advanced practice settings.

Residents who successfully complete an accredited PGY-2 pharmacy residency are prepared for advanced patient care, academic, or other specialized positions, along with board certification, if available.

Program highlights

The program provides the high-quality didactic and clinical experiences needed to create a well-rounded, fully competent oncology pharmacist. PGY-2 oncology pharmacy residents:

• Develop expertise, knowledge and skills in oncology therapies
• Contribute to interdisciplinary health care team offering patient-specific therapeutic interventions to treat, cure, rehabilitate and alleviate medical conditions and diseases unique to cancer patients
• Enhance skills in conducting clinical research while participating in opportunities at the forefront of cancer care
• Strengthen communication skills by presenting formal and informal lectures to multi-disciplinary audiences and learners of all levels, writing a professional manuscript, and leading interdisciplinary discussions
• Work with variety of mentors in all facets of residency curriculum to aid in development and career path
• Tailor exceptional hematology/oncology experience to best suit future career goals

Program history

The PGY-2 Pharmacy Residency in Oncology at Mayo Clinic Hospital — Rochester was accredited by the American Society of Health-System Pharmacists (ASHP) in 2003 and has produced respected clinicians who practice across the U.S. The residency program is continuously evaluated for improvement opportunities to ensure graduates make a seamless transition into clinical practice. Threecandidates per year are selected on a competitive basis.

Facilities

Mayo Clinic Cancer Center is a National Cancer Institute-designated comprehensive cancer center with an international presence. More than 135,000 people receive cancer treatment at Mayo Clinic each year, making it one of the largest cancer treatment facilities in the nation. Hundreds of clinical trials led by Mayo Clinic physicians and scientists are available for patients, including trials through the Alliance for Clinical Trials in Oncology, Phase I Program, Phase II Consortium and Cancer Prevention Network.

Additional trials are available through cooperative research affiliations and collaborations with the National Cancer Institute and other clinical trial groups. Training for this residency is primarily conducted at Mayo Clinic Hospital — Rochester, though students may have learning experiences at Mayo Clinic's outpatient complex.